Pharmacological basis of pegylated liposomal doxorubicin: Impact on cancer therapy
Pharmacological basis of pegylated liposomal doxorubicin: Impact on cancer therapy
复制标题
DOI：
10.1016/j.ejps.2011.09.006
复制
发表时间：
2012-03-12
影响因子：
4.6
通讯作者：
Grenader, Tal
中科院分区：
文献类型：
--
作者：
Gabizon, Alberto;Shmeeda, Hilary;Grenader, Tal
我们在这里审查的聚乙二醇化脂质体阿霉素（PLD）的安全性和有效性的重要影响，这一重要的代理商的各种药理学方面。特别是，PLD的配方特性和它的长循环时间和肿瘤的高微血管通透性和PLD在肿瘤中的选择性积累之间的关系进行了讨论。重点是PLD的药效学效应的药代动力学参数的相关性。药物干扰PLD清除的证据及其临床意义进行了讨论。我们提出了一个简化的血浆PLD检测协议监测PLD清除，作为一种工具，为临床医生控制的安全性和治疗剂量水平的PLD在个别患者的水平。PLD丰富的临床经验进一步加强了其在各种恶性肿瘤管理中的安全性和有效性方面的附加价值。(C)2011 Elsevier B.V.保留所有权利。
We review here various pharmacological aspects of pegylated liposomal doxorubicin (PLD) which have important implications on the safety and efficacy profile of this important agent. Particularly, the formulation properties of PLD and its long circulation time and the relationship between the high microvascular permeability of tumors and the selective accumulation of PLD in tumors are addressed. Emphasis is given to the correlation of pharmacokinetic parameters with pharmacodynamic effects of PLD. The evidence for drug interference with PLD clearance and its clinical relevance are discussed. We propose a simplified plasma PLD testing protocol for monitoring PLD clearance, as a tool for the clinician to control the safety and therapeutic dose level of PLD at an individual patient level. The enriched clinical experience with PLD has further strengthened its added value with regard to both safety and efficacy in the management of a broad variety of malignancies. (C) 2011 Elsevier B.V. All rights reserved.